Literature DB >> 2183594

Treatment of pain in adults with sickle cell disease.

S K Ballas1.   

Abstract

The treatment of an adult patient with sickle cell disease whose clinical course is characterized by frequent painful crises creates a number of logistic problems in a tertiary care city hospital. Because such patients usually have no objective signs of painful crises, they are often considered to be malingerers and drug abusers. This paper reviews this controversial issue and presents one attempt at its resolution.

Entities:  

Mesh:

Year:  1990        PMID: 2183594     DOI: 10.1002/ajh.2830340111

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  6 in total

1.  MRI of soft tissue abnormalities: a primary cause of sickle cell crisis.

Authors:  F Feldman; A Zwass; R B Staron; N Haramati
Journal:  Skeletal Radiol       Date:  1993-10       Impact factor: 2.199

2.  Chart Card: feasibility of a tool for improving emergency department care in sickle cell disease.

Authors:  Lynne Neumayr; Steven Pringle; Stephen Giles; Keith C Quirolo; Susan Paulukonis; Elliott P Vichinsky; Marsha J Treadwell
Journal:  J Natl Med Assoc       Date:  2010-11       Impact factor: 1.798

3.  Detecting the emergence of chronic pain in sickle cell disease.

Authors:  Mark Hollins; Gregory L Stonerock; Nkaku R Kisaalita; Susan Jones; Eugene Orringer; Karen M Gil
Journal:  J Pain Symptom Manage       Date:  2012-05-11       Impact factor: 3.612

Review 4.  From Individualized Treatment of Sickle Cell Pain to Precision Medicine: A 40-Year Journey.

Authors:  Samir K Ballas
Journal:  J Clin Med Res       Date:  2016-03-20

5.  Observations on the management of acute pain crisis in adult sickle cell disease in eastern Saudi Arabia.

Authors:  Emmanuel Udezue; Abdel Moneim Girshab
Journal:  Ann Saudi Med       Date:  2005 Mar-Apr       Impact factor: 1.526

Review 6.  Sickle cell anaemia: progress in pathogenesis and treatment.

Authors:  Samir K Ballas
Journal:  Drugs       Date:  2002       Impact factor: 9.546

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.